Related articles
-
NewsScientists investigate gut microbiota in elderly patients with acute hepatitis E infection
A new study of the impact of hepatitis E virus infection on the gut microbiota identifies a bacterial species as a potential biomarker for disease outcomes.
-
NewsVanderbilt and Parse Biosciences collaborate on new measles treatment
Vanderbilt University Medical Center and Parse Biosciences, an innovator in single-cell sequencing, are collaborating on a new treatment to help unvaccinated measles victims, as the U.S. measles outbreak has now reached its highest case count in 30 years.
-
NewsNew study suggests Florida has the potential for local Chagas disease transmission
Researchers in Florida have discovered local kissing bugs are harboring the parasite that can lead to Chagas disease, demonstrating that this rare, chronic disease has a secure foothold in the U.S. and warrants more preventative measures.
More from News
-
NewsAI used to create protein that kills E. coli
Scientists have used artificial intelligence (AI) to generate a ready-to-use biological protein that can kill antibiotic resistant bacteria like E. coli.
-
NewsInsights for future research and practical approaches in truncal acne
In a new study, researchers have systematically described the mechanisms of truncal acne, evaluated the methods and evaluated the mechanisms, targets, and pros/cons of several treatment products to guide clinical choices.
-
NewsFlightpath Biosciences licenses microbiome-sparing antibiotic developed at Illinois
Flightpath Biosciences, Inc., has licensed a class of antibiotics developed at the University of Illinois Urbana-Champaign. The original antibiotic agent, lolamicin, effectively treated bacterial infections in animal models of disease without wiping out beneficial gut microbes.
No comments yet